Literature DB >> 865583

Complete deficiency of adenine phosphoribosyltransferase. Report of a family.

K J Van Acker, H A Simmonds, C Potter, J S Cameron.   

Abstract

We studied the clinical and biochemical manifestations of complete adenine phosphoribosyltransferase deficiency in the kindred of a male homozygous child excreting stones of 2,8-dihydroxyade-nine. Abnormal amounts of adenine, 8-hydroxyade-nine and 2,8-dihydroxyadenine (25 per cent of total purine metabolites) appeared in the urine of the propositus and his clinically normal brother, but not in heterozygotes or a control. Adenine phosphoribosyl-transferase activity in erythrocytes was less than 1 per cent of normal in both homozygotes and varied from 20 to 57 per cent of normal in six heterozygotes. Heterozygotes exhibited neither hyperuricemia nor gout. Treatment of the propositus with allopurinol and a low purine diet stopped stone formation. In addition, excretion of 2,8-dihydroxyadenine decreased. An autosomal recessive mode of inheritance with variable expression in the phenotype is indicated. Homozygotes may be detected by their raised urinary adenine levels or absence of detectable erythrocyte adenine phosphoribosyltransferase activity (or both).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 865583     DOI: 10.1056/NEJM197707212970302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  Immunological and purine enzyme studies on hyperuricaemic and normouricaemic patients with Down's syndrome.

Authors:  R W Watts; Y S Perera; J Allsop; C Newton; T A Platts-Mills; A D Webster
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

Review 2.  Congenital/inherited kidney diseases: how to identify them early and how to manage them.

Authors:  Jean-Pierre Grünfeld
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

3.  An infant with nephrolithiasis and renal failure: Answers.

Authors:  Kazuyuki Ueno; Masaki Shimizu; Tatsuya Kubo; Noboru Igarashi; Kiyoshi Hatasaki
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

4.  Adenine phosphoribosyltransferase deficiency in children.

Authors:  Jérôme Harambat; Guillaume Bollée; Michel Daudon; Irène Ceballos-Picot; Albert Bensman
Journal:  Pediatr Nephrol       Date:  2012-01-03       Impact factor: 3.714

5.  Rapid method for the diagnosis of partial adenine phosphoribosyltransferase deficiencies causing 2,8-dihydroxyadenine urolithiasis.

Authors:  F Takeuchi; K Matsuta; T Miyamoto; S Enomoto; S Fujimori; I Akaoka; N Kamatani; K Nishioka
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

6.  APRT deficiency: the need for early diagnosis.

Authors:  Aamira Huq; Kushma Nand; Rajiv Juneja; Ingrid Winship
Journal:  BMJ Case Rep       Date:  2018-10-23

7.  Selection of human cells having two different types of mutations in individual cells (genetic/artificial mutants). Application to the diagnosis of the heterozygous state for a type of adenine phosphoribosyltransferase deficiency.

Authors:  N Kamatani; S Kuroshima; C Terai; K Kawai; K Mikanagi; K Nishioka
Journal:  Hum Genet       Date:  1987-06       Impact factor: 4.132

8.  Adenine phosphoribosyltransferase-deficient mice develop 2,8-dihydroxyadenine nephrolithiasis.

Authors:  S J Engle; M G Stockelman; J Chen; G Boivin; M N Yum; P M Davies; M Y Ying; A Sahota; H A Simmonds; P J Stambrook; J A Tischfield
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  Human adenine phosphoribosyltransferase: characterization from subjects with a deficiency of enzyme activity.

Authors:  T E O'Toole; J M Wilson; M H Gault; W N Kelley
Journal:  Biochem Genet       Date:  1983-12       Impact factor: 1.890

10.  Human adenine phosphoribosyltransferase. Identification of allelic mutations at the nucleotide level as a cause of complete deficiency of the enzyme.

Authors:  Y Hidaka; T D Palella; T E O'Toole; S A Tarlé; W N Kelley
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.